![Mark Vickery Mark Vickery](https://staticx.zacks.com/images/mugshots/mark_vickery/mark_vickery-8.png)
Top Stock Reports for U.S. Bancorp, Bristol-Myers Squibb & Morgan Stanley
![](https://staticx.zacks.com/images/zt/ztNow_icon2.png)
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tuesday, October 22, 2019
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including U.S. Bancorp (USB), Bristol-Myers Squibb (BMY) and Morgan Stanley (MS). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
U.S. Bancorp’s shares have outperformed the Zacks Major Banks industry year to date (22.6% vs. 21.9%). The Zacks analyst believes that U.S. Bancorp’s solid business model, core franchise and diverse revenue streams are expected to continue supporting its performance.
The company possesses an impressive earnings surprise history, having beaten the Zacks Consensus Estimate in three of the trailing four quarters. Third-quarter results benefited from higher revenues and loan growth. Further, rising loans and deposit balances have strengthened the company's balance sheet, enabling it to undertake strategic acquisitions.
Moreover, improved credit quality is a tailwind for the company. However, escalating costs due to its ongoing investments in technology and the likely increase in legal expenses remain concerns. Also, significant exposure to commercial loans remains a headwind for the company.
(You can read the full research report on U.S. Bancorp here >>>)
Shares of Bristol-Myers have gained 16.6% in the past six months against the Zacks Large Cap Pharmaceuticals industry’s rise of 2.4%. The Zacks analyst believes that Bristol-Myers’ lead immuno-oncology drug, Opdivo, continues to drive growth. Label expansion of the drug into additional indications should boost the top line. Empliciti and Sprycel are also performing well on label expansions.
Moreover, Bristol-Myers also has presence in other core therapeutic areas, including immunoscience and cardiovascular. Blood thinner drug, Eliquis, is also expected to drive growth. Meanwhile, the impending acquisition of Celgene will broaden the company’s oncology portfolio with the addition of Revlimid.
However, pipeline setbacks are a concern. The failure of the part 2 of the Checkmate-227 study was disappointing, given the potential in the NSCLC market. Earnings estimates are stable ahead of third-quarter results.
(You can read the full research report on Bristol-Myers here >>>)
Morgan Stanley’s shares have lost 1% over the past three months against the Zacks Investment Banking industry’s decline of 5.9%. The Zacks analyst believes the acquisition of Solium Capital is in sync with the company’s efforts to further strengthen its wealth management business.
The company has an impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in three of the trailing four quarters. Its third-quarter 2019 results show improvement in trading and investment banking operations.
Its focus on corporate lending business, steady loan growth and strong balance sheet will continue to aid profitability. However, weaknesses in investment banking and trading are expected to hinder fee income growth and the top line. Also, given the expectation of more rate cuts and a tough operating backdrop, the company’s performance is expected to remain sluggish in the near term.
(You can read the full research report on Morgan Stanley here >>>)
Other noteworthy reports we are featuring today include TOTAL (TOT), Bank of America (BAC) and Gilead Sciences (GILD).
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.50% per year. So be sure to give these hand-picked 7 your immediate attention.
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Get the latest research report on BAC - FREE
Get the latest research report on MS - FREE
Get the latest research report on BMY - FREE
Get the latest research report on GILD - FREE
Get the latest research report on USB - FREE